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RESUMO – Alopecia fibrosante em padrão de distribuição androgenética é uma forma clínica de alopecia cicatricial recentemente 
reconhecida, manifestando-se por rarefacção de cabelo na área dependente de androgénios. Ausência de orifícios foliculares, eri-
tema e hiperqueratose peri-pilar, e anisotriquia são as pistas em tricoscopia e o infiltrado inflamatório liquenóide folicular achado 
importante em histopatologia. Partilha características de alopecia androgenética e líquen plano pilar. Os dermatologistas devem 
estar familiarizados com esta entidade, a fim de otimizar o diagnóstico e tratar precocemente, evitando dano folicular irreversível. 
PALAVRAS-CHAVE – Alopecia/diagnóstico; Alopecia/epidemiologia; Alopecia/tratamento farmacológico; Fibrose. 
Fibrosing Alopecia in a Pattern Distribution: 
Pathogenesis, Diagnosis and Treatment   
ABSTRACT – Fibrosing alopecia in a pattern distribution is a recently recognized type of scarring alopecia, with hair loss in an-
drogens-dependent area. Loss of follicular openings, perifollicular erythema, perifollicular hyperkeratosis and anisotriquia are the 
trichoscopic clues and follicular lichenoid inflammatory infiltrate the important finding in histopathology. It shares features of an-
drogenetic alopecia and lichen planopilaris. Dermatologists should be familiarized with this entity in order to optimize the diagnosis 
and provide early treatment to prevent irreversible follicular damage.  
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INTRODUCTION
Fibrosing alopecia in a pattern distribution (FAPD) was 
initially described by Zinkernagel and Trueb in 2000,1 as a 
distinct type of lymphocytic scarring alopecia. It is charac-
terized by a combination of clinical, trichoscopic and histo-
pathological features of both lichen planopilaris (LPP) and 
androgenetic alopecia (AGA).1,2-11 FAPD may also coexist 
with frontal fibrosing alopecia (FFA).2
AGA is the most common form of non-scarring alopecia, 
caused by hair thinning on androgen dependent scalp.3 In 
women, most often, a diffuse hair loss occurs in all andro-
genetic area with maintenance of the frontal hairline (Lu-
dwig pattern). Male pattern is characterized by bi-temporal 
recession of the frontal hairline, followed by diffuse thinning 
at the vertex (Hamilton-Norwood pattern).3
Classic LPP is an immune-mediated alopecia with chronic 
lymphocytic inflammation that leads to the selective destruc-
tion of hair follicles, resulting in scarring alopecia, with hair 
loss in patchy areas.4 FFA was once considered a subtype of 
LPP with selective involvement of the frontal-temporal hair-
line and eyebrows, but nowadays is considered a separate 
clinical entity.5
In FAPD, unlike LPP, we find vellus hair and hair loss in a 
pattern distribution involving the androgen-dependent scalp 
(similar to AGA). Unlike AGA, we find many focal areas 
of cicatricial alopecia, peripilar erythema and peripilar 
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hyperkeratosis in trichoscopy and lichenoid inflammation in 
histopathology.1,2,6-9
It has been first described in Caucasians but may also 
affect Hispanics and African-descents.2,6,9 It is more common 
in women, most often in post-menopause or peri-menopause. 
It is rare in men and may develop at a younger age.2,6,9,11-15
This entity may easily be misdiagnosis as AGA with concur-
rent seborrheic dermatitis, with delay in the diagnosis and con-
sequent fibrosis progression, leading to irreversible alopecia.
PATHOGENESIS
It has been suggested that FAPD is a variant of LPP10 
or a lichenoid scarring variant of AGA.11 The last hypothe-
sis is favored by the variable peri-follicular micro-inflam-
mation observed in histopathology in many cases of AGA. 
The cause for the location of a lichenoid infiltrate primarily 
around miniaturized hair follicles is unknown. Some au-
thors propose that the damaged hair follicles may express 
different cytokines, initiating a repairing inflammatory pro-
cess or an apoptosis-mediated organ deletion.2,6 Others 
suggest that the lichenoid reaction may be caused by unk-
nown antigenic stimulus on altered AGA hair follicles in 
immunogenetically susceptible patients.2,8 Androgens may 
play a role, considering that anti-androgen therapy de-
creases scalp inflammation in some cases and stabilizes 
hair loss progression.2,9,10 
There is one report of familial occurrence of FFA and 
FAPD in both mother and daughter, suggesting nosologi-
cal relationship between the two conditions with respect to 
both the androgenetic background and the inflammatory 
reaction pattern.10,13 Further studies are necessary to un-
derstand the pathophysiology of FAPD.
DIAGNOSIS
FAPD can be diagnosed by combination of physical 
exam, trichoscopy and histopathology.  The main differen-
tial diagnoses are AGA, AGA plus seborrheic dermatitis 
and classic LPP. 
Clinically, FAPD presents with patterned hair loss in-
volving androgen dependent scalp - Ludwig pattern in 
women (Fig. 1) and Hamilton-Norwood pattern in men – 
with slowly progressive course. Some patients complain of 
scalp symptoms such as dysesthesia, pain, burning sensa-
tion and pruritus.2,16 Physical exam reveals low hair density 
and sometimes peri-follicular erythema, follicular hyperke-
ratosis and absence of follicular openings may be detec-
ted by open eye.2,9 Rare skin findings are frontal hairline 
recession similar to FFA, red dots in reticulated pattern on 
the chest and facial papules.2,17,18 FAPD may affect the eye-
brows, but unlike FFA, FAPD is not known to affect eyela-
shes or other body hair.17,18 Patchy or asymmetric hair loss 
should be excluded for the diagnosis of FAPD.2
Regarding trichoscopy, the most important distin-
guishing findings between FAPD (Fig. 2) and AGA (Fig. 3) 
are loss of follicular openings, perifollicular erythema, and 
perifollicular hyperkeratosis. The last may have a tubular 
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Figure 1 - FAPD in a 60-year-old woman, with hair loss on the crown 
resembling androgenetic alopecia.   
Figure 2 - FAPD Trichoscopy: coexistence of vellus and terminal 
hair, mild peripilar scaling activity, with peripilar casts surrounding the 
emergence of tuft of 4 hairs (white arrow), mild interpilar erythema and 
micro-islands with no follicular orifices (scarring alopecia).   
Figure 3 - AGA Trichoscopy: anisotrichia greater than 20%, without 
peripilar activity.
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shape around the hair: peripilar casts. When surrounding 
the emergence of a tuft of 2-3 hairs, they are very typical 
and represents the optimal biopsy site for histologic diag-
nosis.2,6-9 Other trichoscopic features are common to AGA, 
like hair diameter variability and predominance of single 
hair follicles. The presence of vellus hair in FAPD helps 
to distinguish it from classic LPP (Fig. 4). In patients with 
dark skin, a honeycomb pigmented network and scattered 
white small patches may also be seen, similar in presen-
tation to what is seen in central centrifugal cicatricial alo-
pecia (CCCA).2,9 Dermoscopy alone may not be sufficient 
to distinguish between CCCA and FAPD in dark-skinned 
patients.
Skin biopsy is important to confirm diagnosis and may 
be performed with a 4-mm punch biopsy, guided by tri-
choscopy and processed with horizontal sections. The best 
locations are peripilar casts. In early lesions, we find a lym-
phohistiocytic infiltrate surrounding the hair follicle in the 
isthmus and infundibular regions and follicular interface 
dermatitis, with vacuolar degeneration of the follicular epi-
theliocytes. Interface dermatitis in inter-follicular epidermis 
is rarely found and lower portions of the follicles, inclu-
ding the hair bulbs, are usually spared. Advanced lesions 
show concentric peri-follicular lamellar fibrosis (Fig. 5) and 
fibrosed follicular tracts.2,6-13,16,17 There is hair follicle mi-
niaturization, apoptosis of the basal keratinocytes and a 
decrease in sebaceous gland number.2,6 In FAPD, the folli-
cular lichenoid reaction affects both miniaturized and non-
-miniaturized follicles in the affected scalp.2
Combination of clinical pattern, trichoscopy and his-
topathology differentiates FAPD from AGA or classic LPP 
(Table 1).6,11,14 The distinction between FAPD and AGA with 
seborrheic dermatitis is easy, because in the latter the sca-
les are observed in the inter-pilar spaces and the follicular 
openings are present. The difference is important, espe-
cially in cases in which hair transplantation is being consi-
dered, because patients with FAPD, similarly to those with 
LPP, might not be good candidates for the procedure due to 
the potential risk of loss of the transplanted hair.2
TREATMENT
There are few available data, limited to small retrospecti-
ve studies and case reports.
The primary treatment goal is to stabilize the progres-
sion of hair loss and a secondary goal is to achieve hair 
regrowth. However, substantial improvement in advanced 
disease is impossible. Available agents aim to decrease 
inflammation and reverse miniaturization.  
Topical corticosteroids are the mostly used anti-inflam-
matory drugs, improving scalp symptoms alone and stabi-
lizing hair loss in combination with other agents. Only in 
one case, stabilization in hair loss with topical clobetasol 
alone was reported.19,20 Topical 0.05% clobetasol propio-
nate (as foam, solution, and shampoo) has been succes-
sfully used combined with 5% minoxidil.16 Triamcinolone 
acetonide 0.2% solution used in combination with 5% topi-
cal minoxidil has also been a successful maintenance the-
rapy.17
Oral hydroxychloroquine is commonly used in both FFA 
and LPP. A few data point its potential benefit in FADP in 
daily dose of 200-400 mg combined with topical therapy 
with clobetasol propionate and 5% minoxidil.2,16,17
Minoxidil is a hair growth promoter, thickening minia-
turized hairs and is often used as complementary treat-
ment in scarring alopecias. In FAPD, topical minoxidil is 
always used in combination with other agents to stabilize 
hair loss.1,16,17 There are no data about using oral minoxidil 
in FAPD.
Antiandrogens drugs, even in monotherapy, may stabi-
lize the disease. One man treated with 1 mg daily finasteri-
de presented both decreased inflammation and hair loss.1 
Finasteride seems to be beneficial in women with FAPD 
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Figure 4 - Trichoscopy: absence of follicular orifices in a large exten-
sion of the field (cicatricial alopecia), mild interpilar erythema and marked 
peripilar activity, consisting of circumferential desquamation(peripilar 
casts) and follicular plugs. Note the absence of vellus hair. 
Figure 5 - FAPD Histopahology: several follicles show perifollicular 
fibrosis and mild lichenoid infiltrate at the upper follicular level. Note 
the involvement of a vellus follicle. (horizontal sections, Hematoxylin 
and eosin, x10). Courtesy of Dr. Maryia Miteva (Miami University).   
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refractory to topical therapy with minoxidil and clobeta-
sol.2,16 There are two successful cases of women treated 
with oral cyproterone acetate combined with topical 5% 
minoxidil and clobetasol propionate,1 but recently there is 
concern about the association between oral cyproterone 
acetate and the occurrence of meningioma.19-21
Although topical retinoids may contribute to hair regrowth 
in patients with AGA, in FAPD no benefit was observed.2
CONCLUSION
FAPD is an entity to consider in the differential diagnoses 
of scarring alopecias.  The scalp shows features of both LPP 
and AGA. Clinical findings, trichoscopic features and histo-
pathology allows us to distinguish between them. Early re-
cognition and proper treatment allow disease stabilization 
the and avoid permanent follicular hair damage. 
KEY-POINTS
- Fibrosing alopecia in a pattern distribution is a scarring 
alopecia with lichenoid 
Inflammation involving miniaturized hair, in androgen-
-dependent scalp.
- Clues for diagnosis are hair loss resembling androge-
netic alopecia and trichoscopic findings of peripilar casts 
and loss of follicular openings. 
- Anti-inflammatory agents in combination with hair 
growth promoters and/or anti-androgen drugs can stabilize 
the disease decreasing hair loss.
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